Tulip Sponsors FDA Study for COVID-19 Patients

Just published in the Journal of Current Medical Research and Opinion

SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial using AD cSVF to treat post-COVID 19 survivors suffering residual lung damage.

Many moderate to severe post-COVID 19 survivors  experience compromised lung function. As a proposed solution,  adipose-derived cellular stromal vascular fraction (AD cSVF) may be  effective in reversing residual damage to the lungs and gas exchange  functions.

Tulip Medical is grateful to have the opportunity to sponsor this trial and provide surgical instrumentation for it.



Share thoughts, questions, and comments on this article.

Leave a Reply

Scroll to Top